

TABLE 3 Patients with NGGCT with progressive disease or relapsed

ID	2	12	23	47	50
Year of Diagnosis	2013	2018	2005	2018	2007
Age	0.8	7.9	11.1	15.4	13.4
Gender	Male	Male	Male	Male	Male
Primary site	Pineal	Thalamus	Intraventricular	Pineal	Pineal
Pretreatment biopsy	Yes	No	Yes	No	Yes
Serum BHCG (IU/L) at diagnosis	N	N	N	5670	108
Serum AFP (ng/ml) at diagnosis	118	11351	7389	N	3857
CSF BHCG (IU/L) at diagnosis	UK	N	N	UK	53.2
CSF AFP (ng/ml) at diagnosis	UK	4760	274	UK	4906
CSF Cytology	Negative	Negative	Negative	Negative	Negative
Baseline spinal imaging	Negative	Negative	Negative	Negative	Negative
Initial Chemotherapy	SIOP	SIOP	SIOP	SIOP	SIOP
Time (m) from diagnosis to chemotherapy	0.39	0.42	0.98	0.26	0.29
Initial RT volume	None	None	None	None	CSI+TB
Initial RT dose (Gy)	0	0	0	0	30.6/50.4
Time (m) from diagnosis to RT	n/a	n/a	n/a	n/a	3.7
Site of relapse	Pineal	TM	TM	Pineal	Pineal
Serum BHCG (IU/L) at relapse	N	N	N	N	N
Serum AFP (ng/ml) at relapse	28.5	10574.1	388	N	266
CSF BHCG (IU/L) at relapse	5	1.3	N	5765	N
CSF AFP (ng/ml) at relapse	N	4768.5	N	N	N
PFS1(m)	3.78	1.45	3.78	3.36	6.97
Salvage treatment 1	GemPox	HDC and ASCT	CSI 36+TB 55.8	TB 54	VP16
PFS2(m)	n/a	n/a	3.75	2.43	n/a
Salvage treatment 2	n/a	n/a	PR	GemPox	n/a
OS (m)	6.58	7.91	15.69	16.45	15.59
Outcome	Dead of disease	Dead of disease	Dead of disease	Dead of disease	Dead of disease

Abbreviations: UK=unknown; N=normal; TB=tumor bed, CSI=craniospinal irradiation, m=months, TM = tumor marker, HDC=high dose chemotherapy, ASCT=autologous stem cell transplant, PEI: Cisplatin – Etoposide – Ifosfamide, GemPox=Gemcitabine – Paclitaxel - Oxaliplatin, ICE=Ifosfamide – Carboplatin – Etoposide, CSF=craniospinal fluid